Drug Profile
Research programme: cardiovascular and metabolic disorder therapeutics - Daiichi Sankyo/Sanford-Burnham Medical Research Institute
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc; Sanford-Burnham Medical Research Institute
- Developer Daiichi Sankyo Inc; Sanford Burnham Prebys Medical Discovery Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Jul 2018 No recent reports of development identified for research development in Metabolic-disorders in USA
- 21 May 2014 Early research in Cardiovascular disorders in USA (unspecified route)